An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer.

Trial Profile

An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2011 Pharmacogenomic analysis results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Feb 2011 Health-related quality of life and colorectal cancer-specific symptom results published in the International Journal of Colorectal Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top